Morgan Stanley Downgrades 2seventy bio to Equal-Weight, Lowers Price Target to $13
Portfolio Pulse from richadhand@benzinga.com
Morgan Stanley analyst Matthew Harrison has downgraded 2seventy bio (NASDAQ:TSVT) from Overweight to Equal-Weight and lowered the price target from $25 to $13.
July 28, 2023 | 9:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
2seventy bio has been downgraded by Morgan Stanley from Overweight to Equal-Weight, with a lowered price target from $25 to $13.
The downgrade from Morgan Stanley, a major financial institution, could negatively impact investor sentiment towards 2seventy bio. The lowered price target suggests that the analyst sees less upside potential in the stock, which could lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100